PE anti-mouse CD279 (PD-1) Antibody

Product Details

Verified Reactivity

Mouse

Antibody Type

Monoclonal

Host Species

Rat

Immunogen

PD-1 cDNA followed by PD-1-Ig fusion protein

Formulation

Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.

Preparation

The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.

Concentration

0.2 mg/ml

Storage & Handling

The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.

Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser

Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)

Application Notes

Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen tissue³, in vivo blocking of PD-1 binding to its ligands^2,3, and spatial biology (IBEX)^5,6.

Application References

(PubMed link indicates BioLegend citation)

1. Good-Jacobson KL, et al. 2010. Nat. Immunol. 11:535. (FC) PubMed
2. Lázár-Molnár E, et al. 2008. Proc. Natl. Acad. Sci. USA 105:2658. (Block)
3. Liang SC, et al. 2003. Eur. J. Immunol. 33:2706. (FC, IHC, Block)
4. Tobias J, et al. 2020. Front Immunol. 11:895 (FC, ELISA) PubMed
5. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
6. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed

Product Citations

1. Harsha Krovi S, et al. 2020. Nat Commun. 4.790277778. PubMed
2. Dong MB, et al. 2020. Cell. 178(5):1189-1204.e23.. PubMed
3. Spitsin S, et al. 2012. Clin Vaccine Immunol. 1.313888889. PubMed
4. Xue G, et al. 2021. Cancer Cell. 39:1610. PubMed
5. Serra M, et al. 2022. Cell Mol Gastroenterol Hepatol. 14:609. PubMed
6. Liu M, et al. 2022. Cells. 11: . PubMed
7. Wei M, et al. 2022. Front Immunol. 13:1017574. PubMed
8. Zhao X, et al. 2022. STAR Protoc. 3:101859. PubMed
9. Domingos-Pereira S, et al. 2022. Int J Mol Sci. 24: . PubMed
10. Wei J, et al. 2022. Cancer Prev Res (Phila). 15:285. PubMed
11. Wight AE, et al. 2022. Proc Natl Acad Sci U S A. 119:e2200757119. PubMed
12. Wu Z, et al. 2023. EMBO Rep. 24:e56524. PubMed
13. Hamdan F, et al. 2023. Mol Ther Oncolytics. 28:264. PubMed
14. Florian DC, et al. 2023. Cancer Res Commun. 3:223. PubMed
15. Gao Y, et al. 2023. iScience. 26:106729. PubMed
16. Nishi W, et al. 2023. Nat Commun. 14:3157. PubMed
17. Yang QC, et al. 2023. iScience. 26:106916. PubMed
18. Renrick AN, et al. 2021. Front Immunol. 607044:12. PubMed
19. Kaczanowska S, et al. 2021. Cell. 184(8):2033-2052.e21. PubMed
20. Lin YN, et al. 2022. Oncoimmunology. 11:2027136. PubMed
21. Zhang R, et al. 2021. Cell Mol Immunol. 18:1222. PubMed
22. Hamilton JAG, et al. 2021. Aging Cell. 20:e13309. PubMed
23. Kim CJ, et al. 2018. Immunity. 49:1034. PubMed
24. Sasse C, et al. 2022. Pathogens. 11:. PubMed
25. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
26. Stolp B, et al. 2022. Cell Rep. 38:110387. PubMed
27. Feizi N, et al. 2021. Cell Death Dis. 12:1026. PubMed
28. Lu SX, et al. 2021. Cell. . PubMed
29. Misumi I et al. 2019. Cell Rep. 27(2):514-524 . PubMed
30. Kummer MP, et al. 2021. EMBO J. 40:e108662. PubMed
31. Cai B, et al. 2021. Mol Cancer. 20:165. PubMed
32. Kramer KJ, et al. 2022. Nat Commun. 13:3466. PubMed
33. Lv H, et al. 2020. Cell Metabolism. 33(1):110-127.e5. PubMed
34. Gary EN, et al. 2021. iScience. 24(7):102699. PubMed
35. Hu J, et al. 2020. Biomed Pharmacother. 127:110229. PubMed
36. Russell SL, et al. 2019. Cell Rep. 29:3564. PubMed
37. Jing L, et al. 2022. Front Immunol. 13:864995. PubMed
38. Wang Z, et al. 2021. J Virol. 95:e0141421. PubMed
39. Zhang X, et al. 2021. Front Immunol. 12:680068. PubMed
40. Domeier P, et al. 2016. J Exp Med. 213: 715 - 732. PubMed
41. Soni C, et al. 2014. J Immunol. 193:4400. PubMed
42. Liu J, et al. 2019. J Exp Med. 216:656. PubMed
43. Wang GZ, et al. 2019. Nat Commun. 10:1125. PubMed
44. Zhang P, et al. 2022. BMC Med. 20:435. PubMed
45. Mintz MA, et al. 2019. Immunity. 51:310. PubMed
46. Ekeke CN, et al. 2020. J Thorac Cardiovasc Surg. S0022-5223:33337. PubMed
47. Zhang YN, et al. 2020. EBioMedicine. 56:102819. PubMed
48. Garo LP, et al. 2019. Cell Rep. 28:3353. PubMed
49. Fortner K, et al. 2017. Journal of Autoimmunity. 10.1016/j.jaut.2017.05.003. PubMed
50. Wei W, et al. 2022. mSystems. 7:e0046922. PubMed
51. Zuo S, et al. 2021. J Immunother Cancer. 9:. PubMed
52. Reinfeld BI, et al. 2021. Nature. 593:282. PubMed
53. Soni C, et al. 2020. Immunity. 52(6):1022-1038.e7. PubMed
54. LaFleur MW, et al. 2019. Nat Commun. 10:1668. PubMed
55. Mittal A, et al. 2021. Sci Rep. 11:10731. PubMed
56. Zhang X, et al. 2020. Endocr Relat Cancer. 27:469. PubMed
57. Pham D, et al. 2019. Cell Rep. 29:1203. PubMed
58. Beloor J et al. 2018. Cell host & microbe. 23(4):549-556 . PubMed
59. Schell S, et al. 2017. J Immunol. 10.4049/jimmunol.1700611. PubMed
60. Chen C, et al. 2021. J Virol. 95:e0082921. PubMed
61. Gomez S, et al. 2022. J Immunother Cancer. 10:. PubMed
62. Zhang C, et al. 2021. J Immunother Cancer. 9:. PubMed
63. Zhao X, et al. 2022. iScience. 25:104690. PubMed
64. Moufarrij S, et al. 2020. Sci Rep. 10:3470. PubMed
65. Liu Y, et al. 2018. Cancer Cell. 33:480. PubMed
66. Wong E, et al. 2015. J Immunol. 194:4130. PubMed
67. Huang WC, et al. 2020. Adv Mater. 32:e2005637. PubMed
68. Fang W, et al. 2021. J Exp Clin Cancer Res. 40:4. PubMed
69. Wagner AK, et al. 2022. iScience. 25:105137. PubMed
70. Lu Y, et al. 2018. Cancer Cell. 33:1048. PubMed
71. Hamdan F, et al. 2021. Journal for ImmunoTherapy of Cancer. 9(8):. PubMed
72. Roberto MP, et al. 2021. Immunity. 54(8):1807-1824.e14. PubMed
73. Zhang Z, et al. 2022. J Inflamm Res. 15:5595. PubMed
74. Fusciello M, et al. 2019. Nat Commun. 4.407638889. PubMed
75. Li X, et al. 2021. Front Immunol. 12:779560. PubMed

RRID

AB_1877231 (BioLegend Cat. No. 135205)
AB_1877231 (BioLegend Cat. No. 135206)

Antigen Details

Structure

A 50-55 kD glycoprotein belonging to the CD28 family of the Ig superfamily.

Distribution

Induced on splenic T and B lymphocytes, thymocytes, and myeloid cells after stimulation.

Function

Involved in lymphocyte clonal selection and peripheral tolerance, prolonged survival of allografts.

Ligand/Receptor

B7-H1 (PD-L1) and B7-DC (PD-L2)

Cell Type

B cells, T cells

Biology Area

Cancer Biomarkers, Immunology, Inhibitory Molecules

Molecular Family

CD Molecules, Immune Checkpoint Receptors

Antigen References

1. Nishimura H, et al. 2001. Science 291:319
2. Agata Y, et al. 1996. Int. Immunol. 8:765
3. Liang SC, et al. 2003. Eur. J. Immunol. 33:2706
4. Barber DL, et al. 2006. Nature 439:682
5. Keir ME, et al. 2005. J. Immunol. 175:7372
6. Koehn BH. et al. 2008. J Immunol. 181:5313

Gene ID

18566 View all products for this Gene ID

UniProt

View information about CD279 on UniProt.org

Documentation

• Technical Data Sheet (pdf)
• Certificate of Analysis
• Safety Data Sheet

Reviews

Related Protocols

• Cell Surface Flow Cytometry Staining Protocol

Related Pages & Pathways

Related FAQs

What type of PE do you use in your conjugates?

We use R-PE in our conjugates.

Other Formats

Certificate of Analysis